Background: Adverse reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) are frequent, particularly among patients with chronic urticaria or asthma. The identification of an alternative safe and reliable drug is a common problem in clinical practice. Objective: To assess the tolerability of rofecoxib, a new NSAID that selectively inhibits the inducible isoform of cyclooxygenase, in a large group of NSAID-sensitive patients. Methods: We studied 216 patients (164 females and 52 males) who had suffered adverse reactions to one or more NSAIDs; 98 subjects (45.4%) had experienced reactions to only one NSAID (single hypersensitivity) and 118 subjects (54.6%) had reacted to multiple NSAIDs (multiple hypersensitivity). Cutaneous reactions were reported by 79.6% of the subjects, respiratory symptoms by 10.7%, cutaneous and respiratory symptoms by 8.3%, anaphylaxis by 1.4%. All the subjects underwent a single-blind, placebo-controlled oral challenge with divided therapeutic doses of rofecoxib (6.25 mg +18.75 mg 1 h later = cumulative dose of 25 mg). Results: No reactions to the placebo were observed; only 1 subject (0.46%) experienced an urticarial reaction, after the second dose of rofecoxib. Conclusions: Considering previous studies and our own data, rofecoxib was well tolerated by all of the 174 patients with exclusively NSAID-related respiratory symptoms. Rofecoxib also had a very low rate (1.6%) of cross-reactivity in the 600 patients with exclusively cutaneous reactions to NSAIDs.

1.
Naldi L, Conforti A, Venegoni M, Troncon MG, Caputi A, Ghiotto E, Cocci A, Moretti U, Velo G, Leone R: Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999;48:839–846.
2.
Namazy JA, Simon RA: Sensitivity to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002;89:542–550.
3.
Stevenson DD: Diagnosis, prevention, and treatment of adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol 1984;74:617–622.
4.
Szczeklik A: Adverse reactions to aspirin and nonsteroidal anti-inflammatory drugs. Ann Allergy 1987;59:113–118.
5.
Czerniawska-Mysik G, Szczeklik A: Idiosyncrasy to pyrazolone drugs. Allergy 1981;36:381–384.
6.
Kowalski ML, Woszczek G, Bienkiewicz B, Mis M: Association of pyrazolone drug hypersensitivity with HLA-DQ and DR antigens. Clin Exp Allergy 1998;28:1153–1158.
7.
Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232–235.
8.
Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G: Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. Br Med J 1975;1:67–69.
9.
Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G: Clinical patterns of hypersensitivity to nonsteroidal anti-inflammatory drugs and their pathogenesis. J Allergy Clin Immunol 1977;60:276–284.
10.
Carmona MJ, Blanca M, Garcia A, Fernandez S, Burgos F, Miranda A, Vega JM, Garcia J: Intolerance to piroxicam in patients with adverse reactions to nonsteroidal antiinflammatory drugs. J Allergy Clin Immunol 1992;90:873–879.
11.
Szczeklik A, Stevenson DD: Aspirin-induced asthma: Advances in pathogenesis and management. J Allergy Clin Immunol 1999;104:5–13.
12.
Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL: Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692–2696.
13.
Vane JR: Towards a better aspirin. Nat New Biol 1994;367:215–216.
14.
Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O’Neil GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I: Rofecoxib: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 1999;290:551–560.
15.
Enrique E, Cisteró-Bahíma A, San Miguel-Moncín MM, Alonso R: Rofecoxib should be tried in NSAID hypersensitivity. Allergy 2000;55:1090.
16.
Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M: Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001;31:219–225.
17.
Zollner TM, Ahlbach S, Kaufmann R, Boehncke WH: Tolerability of a selective COX-2 inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents. Dtsch Med Wochenschr 2001;126:386–388.
18.
Stevenson DD, Simon RA: Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001;108:47–51.
19.
Hinrichs R, Ritzkowsky A, Hunzelmann N, Krieg T, Scharffetter-Kochanek K: Rofecoxib as an alternative in Aspirin hypersensitivity. Allergy 2001;56:789.
20.
Sánchez Borges M, Capriles-Hulett A, Caballero-Fonseca F, Pérez CR: Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 2001;87:201–204.
21.
Asero R: Tolerability of rofecoxib. Allergy 2001;56:916–917.
22.
Berges-Gimeno MP, Camacho-Garrido E, Garcia-Driguez RM, Alfaya T, Martin Garcia C, Hinojosa M: Rofecoxib safe in NSAID hypersensitivity. Allergy 2001;56:1017–1018.
23.
Nettis E, Di Paola R, Ferrannini A, Tursi A: Tolerability of rofecoxib in patients with cutaneous adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2002;88:331–334.
24.
Pacor ML, Di Lorenzo G, Biasi D, Barbagallo M, Corrocher R: Safety of rofecoxib in subjects with a history of adverse cutaneous reactions to aspirin and/or nonsteroidal anti-inflammatory drugs. Clin Exp Allergy 2002;32:397–400.
25.
Martin-Garcia C, Hinojosa M, Berges P, Camacho E, Garcia-Rodriguez R, Alfaya T, Iscar A: Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma. Chest 2002;121:1812–1817.
26.
Quiralte J, de San Pedro BS, Florido JJF: Safety of selective COX-2 inhibitor rofecoxib in patients with NSAIDs-induced cutaneous reactions. Ann Allergy Asthma Immunol 2002;89:63–66.
27.
Valero A, Baltasa M, Enrique E, Pau L, Dordal MT, Cistero A, Marti E, Picado C: NSAID-sensitive patients tolerate rofecoxib. Allergy 2002;57:1214–1215.
28.
Johansson SGO, Hourihane JO’B, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, Kowalski ML, Mygind N, Ring J, van Cauwenberge P, van Hagen-Hamsten M, Wüthrich B: A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001;56:813–824.
29.
Papa G, Romano A, Del Bono A, Quaratino D, Di Fonso M, Pocobelli D, Giuffreda F, Venuti A: Floctafenine: a valid alternative in patients with adverse reactions to non steroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 1997;78:74–78.
30.
Quaratino D, Romano A, Papa G, Di Fonso M, Giuffreda F, D’Ambrosio FP, Venuti A: Long-term tolerability of nimesulide and acetaminophen in nonsteroidal anti-inflammatory drug-intolerant patients. Ann Allergy Asthma Immunol 1997;79:47–50.
31.
Quaratino D, Romano A, Di Fonso M, Papa G, Perrone MR, Purello D’Ambrosio F, Venuti A: Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2000;84:613–617.
32.
Ispano M, Fontana A, Scibilia J, Ortolani C: Oral challenge with alternative nonsteroidal anti-inflammatory drugs (NSAIDs) and acetaminophen in patients intolerant to these agents. Drugs 1993;46(suppl 1):253–256.
33.
Passalacqua G, Milanese M, Mincarini M, Ciprandi G, Guerra L, Scordamaglia A, Canonica GW: Single-dose oral tolerance test with alternative compounds for the management of adverse reactions to drugs. Int Arch Allergy Immunol 2002;129:242–247.
34.
SIAIC Memorandum on drugs allergy/intolerance diagnosis. Ital J Allergy Clin Immunol 1998;8:568–595.
35.
Delaney JC: The diagnosis of aspirin idiosyncrasy by analgesic challenge. Clin Allergy 1976;6:177–181.
36.
Falliers CJ: Acetaminophen and aspirin challenges in subgroups of asthmatics. J Asthma 1983;20:39–49.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.